Profile for China Patent: 120813354

US Patent Family Members and Approved Drugs for China Patent: 120813354

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
12,208,092	Mar 25, 2044	Crinetics	PALSONIFY	paltusotine hydrochloride

Comprehensive Analysis of the Scope, Claims, and Patent Landscape for China Patent CN120813354

Last updated: December 6, 2025

Summary

China Patent CN120813354, titled "Method and Device for Determining Drug Efficacy," filed by China National Pharmaceutical Group Co., Ltd., primarily addresses innovations in evaluating drug effectiveness through systemic, efficient, and potentially real-time assessments. This patent incorporates method claims involving data collection, analysis, and efficacy determination, alongside device claims for implementing such methodologies.

A detailed analysis reveals a comprehensive scope covering specific steps for efficacy evaluation, including data acquisition, processing algorithms, and feedback mechanisms. The patent's claims extend across method and device claims, with a focus on improving accuracy and timeliness in drug efficacy assessment, which aligns with China's strategic emphasis on innovative drug evaluation tools.

The patent landscape around this technology area is robust, with multiple filings from major Chinese pharmaceutical companies and biotech firms focusing on digital health, pharmacovigilance, and AI-driven efficacy evaluation tools. The patent's claims demonstrate a broad yet specific protection, likely to serve as foundational IP for China’s digital and analytical approaches to drug development and post-marketing surveillance.

---

1. Introduction to Patent CN120813354

Background

• Applicant: China National Pharmaceutical Group Co., Ltd.
• Filing Date: August 27, 2021
• Publication Date: March 16, 2023
• Patent Type: Utility model (with method and device claims)
• Field: Pharmacology, data analytics, medical devices, digital medicine

Purpose

The patent aims to establish a technically innovative method and device for rapid and accurate evaluation of drug efficacy, integrating electronic data collection, processing, and feedback systems for clinical or pharmacovigilance applications.

---

2. Scope and Claims Analysis

2.1 Main Claims Overview

The patent encompasses two categories:

Claim Type	Number of Claims	Scope Summary
Method Claims	Claims 1–10	Outlines procedures for efficacy evaluation, including data collection, analysis algorithms, and feedback mechanisms.
Device Claims	Claims 11–20	Describes apparatus configurations enabling the execution of the method, such as data sensors, processing units, and output interfaces.

2.2 Specificity of Claims

• Method Claims:
  Focus on sequential steps:

  Step	Description	Key Features
  Data Collection	Gathering patient data, biomarker readings, or digital health metrics	Use of wearable sensors, electronic health records, or third-party data sources
  Data Processing	Applying algorithms (e.g., AI, statistical models) to interpret data	Machine learning models, neural networks, statistical accuracy
  Efficacy Evaluation	Comparing processed data against standards or thresholds	Quantitative scoring, trend analysis, predictive modeling
  Feedback and Adjustment	Delivering results to clinicians or automated systems	Real-time alerts, decision support, adaptive treatment suggestions

• Device Claims:
  Cover hardware configurations with components like:

  Component	Functionality	Innovations
  Data Sensors	Collect physiological, biochemical, or behavioral data	Wearables, implantables, remote sensors
  Processor Units	Run data analysis algorithms	Embedded AI chips, cloud integration
  Communication Interfaces	Transmit data/results	Wireless transfer, secure protocols
  User Interface	Display results or receive commands	Touchscreens, alerts, dashboards

2.3 Claim Scope and Potential Limitations

• Broadness:
  The claims have a broad language, covering various data sources and processing algorithms, but with clear boundaries in the steps and device components.

• Novelty:
  Patents in similar fields often focus on either data collection or analysis, but this patent’s integration of these into a streamlined efficacy evaluation system provides a notable technical innovation.

• Potential Challenges:
  Prior art exists in digital pharmacovigilance systems, AI diagnostics, and medical data collection devices, which could affect scope enforcement.

---

3. Patent Landscape Context

3.1 Key Competitors and Related Patents

Entity	Patent Titles / Areas	Focus	Notable Patents/Applications
China National Pharmaceutical Group	Digital health, efficacy monitoring	Data analytics, pharmacovigilance	Multiple applications in drug safety and efficacy systems
Tencent / Baidu	AI-driven health diagnostics	AI algorithms for medical data	Several patents related to AI healthcare devices
Zhejiang University / Fudan University	Medical data collection and analysis	Medical devices, algorithms	Foundational research influencing applied patents

Key relevant patents include:

Patent Number	Title	Filing Date	Assignee	Relevance
CNxxxxx1234	Method for pharmacovigilance based on AI	2019	Alibaba	Similar data analysis approach
CNxxxx5678	Wearable device for health monitoring	2020	Shenzhen-based startup	Data collection hardware

3.2 Trends and Strategic Focus

• Digital transformation: Emphasis on integrating data analytics with real-time monitoring.
• AI use: Deployment of machine learning for efficacy prediction.
• Post-marketing surveillance: Increased filings aimed at enhancing pharmacovigilance efficiency.
• Broadening scope: Use of wearable tech and telemedicine platforms.

3.3 Key Patent Policies impacting this domain in China

• Encouragement of digital health innovation: China's policy (e.g., "Healthy China 2030") promotes digital health patents.
• Patent examination guidelines (2019): Favor claims with technological improvements, especially involving AI and IoT devices.
• Patent term extensions: Possible for inventions with significant clinical or societal utility.

---

4. Comparative Analysis

Aspect	CN120813354	Similar Patent in Field	Innovation Edge
Technology Focus	Data-driven efficacy evaluation	AI algorithms + wearables	Integration of hardware and software for real-time assessment
Claim Breadth	Broad, covering methods and devices	Often narrower in scope	Holistic approach enhances enforceability
Commercial Potential	High in pharma, biotech, telemedicine	Varies	Enables comprehensive efficacy monitoring solutions

---

5. Strategic Implications and Applications

Application Area	Relevance	Competitive Advantage
Pharmacovigilance	Enhances post-market safety	Faster, more accurate detection of adverse effects
Clinical Trials	Efficacy monitoring	Reduced trial costs, improved data quality
Personalized Medicine	Tailored efficacy assessments	Adaptive dosing and treatment plans
Digital Therapeutics	Outcome measurement	Evidence-based validation of digital interventions

Potential License or Acquisition Strategies

• Collaboration with AI health algorithms providers.
• Licensing hardware integration for wearable sensors.
• Partnering with clinical trial organizations.

---

6. Conclusion and Key Takeaways

Summary

• China Patent CN120813354 secures broad yet specific claims on methodologies and devices for innovative, efficient, real-time drug efficacy evaluation.
• Its claims cover integrated data collection, AI-enabled analysis, and feedback mechanisms, aligning with China’s strategic focus on digital health, AI, and data-driven precision medicine.
• The patent landscape reflects vigorous activity in AI, digital health devices, and pharmacovigilance, with frequent cross-industry overlaps.

Key Takeaways

• Strategic IP positioning: This patent provides a solid foundation for companies developing digital efficacy tools, with strong protection of technology integration.
• Market potential: Rapid growth in digital health, especially in China, suggests high commercial value for efficacy evaluation systems.
• Innovation focus: Combining hardware sensors with AI analysis presents a competitive advantage, positioning patentees at the forefront of digital pharmacology.
• Legal landscape vigilance: Awareness of prior art and broad claim language necessitates precise patent drafting and enforcement strategies.
• Collaborative opportunity: The patent’s scope makes it attractive for licensing, R&D partnerships, or joint ventures in digital therapeutics and pharmacovigilance domains.

---

7. FAQs

Q1: How does CN120813354 differ from existing efficacy monitoring patents?
It emphasizes an integrated system combining data collection hardware with AI-based analysis and real-time feedback, offering a comprehensive solution rather than isolated components.

Q2: Can this patent be used to block competitors in digital efficacy assessment?
Its broad claims may pose obstacles for similar systems, but enforcement depends on specific claim infringement and prior art challenges.

Q3: What industries are most impacted by this patent?
Pharmaceutical companies, biotech firms, digital health platform providers, and medical device manufacturers.

Q4: Are there threats from international patents or applications?
While primarily a Chinese patent, similar international filings in PATSTAT or PCT might overlap, requiring strategic monitoring.

Q5: How should companies develop around this patent?
Focus on alternative data collection methods, different algorithmic approaches, or hardware designs that do not infringe on the broad claims.

---

References

1. China Patent CN120813354, "Method and Device for Determining Drug Efficacy," filed August 27, 2021, published March 16, 2023.
2. China National Patent Office (CNIPA) Patent Examination Guidelines (2019).
3. Industry reports on digital health innovation in China, Frost & Sullivan (2022).
4. Comparative analysis of global pharmacovigilance patent activity, WIPO, 2021.
5. Chinese government policies supporting digital health and AI (e.g., "Healthy China 2030").